Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes

PURPOSE: We set out to determine whether clinically tested epigenetic drugs against class I histone deacetylases (HDACs) affect hallmarks of the metastatic process. METHODS: We treated permanent and primary renal, lung, and breast cancer cells with the class I histone deacetylase inhibitors (HDACi)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cancer Res Clin Oncol
Autors principals: Kiweler, Nicole, Wünsch, Désirée, Wirth, Matthias, Mahendrarajah, Nisintha, Schneider, Günter, Stauber, Roland H., Brenner, Walburgis, Butter, Falk, Krämer, Oliver H.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article – Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985217/
https://ncbi.nlm.nih.gov/pubmed/31932908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-019-03118-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars